M&A / Deals Teva makes its first M&A play in years, buying Emalex PharmaphorumTeva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.Read full story pharminent April 30, 2026 (Last updated: April 30, 2026) Pharmaphorum Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m. Read full story Post navigation Previous: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolioNext: Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026